Previous 10 | Next 10 |
Overactive mTOR Plays a Key Role in Aging and Alzheimer’s Disease. Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect. Research is Published in Frontiers in Aging , a Peer-reviewed Journal. AUSTIN, Texas, June 27, 2023 (GLO...
NEW ORLEANS, June 24, 2023 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Cassava Sciences, Inc. (NasdaqCM: SAVA). Beginn...
2023-06-20 07:27:39 ET Summary Cassava Sciences' results from the 6-month randomized CMS, using simufilam for the treatment of mild-to-moderate AD patients, are expected to be released in Q3 of 2023. It is expected that the global Alzheimer's Disease market could reach $6.3 billio...
Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research , a Peer-Reviewed Journal. AUSTIN, Texas, June 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences...
2023-06-11 12:00:02 ET Driven by novel therapeutics from Biogen ( NASDAQ: BIIB )/ Eisai ( OTCPK:ESALF ) and Eli Lilly ( NYSE: LLY ), the Alzheimer’s disease market across eight major countries will reach $13.7B in 2030, the data analytics firm, GlobalData said las...
2023-06-08 14:30:41 ET If you’re like most traders in the stock market today, penny stocks are something to get familiar with. Now, keep in mind, I say “traders” and not “investors” for a reason. In many cases, these cheap stocks fluctuate rapidly in p...
AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City. ...
2023-05-23 17:06:29 ET Summary Cassava stock - incredibly volatile between 2020-2022 - hasn't increased much in value in the last year. The company's Alzheimer's candidate Simufilam remains in Phase 3 studies with data likely arriving in 2024. The company remains heavily short...
2023-05-18 10:59:22 ET S3 Partners dug into the short interest data on U.S. stocks to find the names that are seeing the most pressure exerted on investors with short positions. Ihor Dusaniwsky filtered the stock universe to pull out squeeze candidates with over $50M worth of short inte...
2023-05-16 14:56:55 ET Summary Blarcamesine, Aricept, and most probably simufilam are sigma-1 receptor agonists. Sigma-1 receptor agonists often produce temporary improvements in cognition for those with mild cognitive impairment and can initially stabilize the disease in mild Alz...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...